周四盘中，疫苗制造商诺瓦瓦克斯医药（NVAX）股价大幅下跌10.05%，引发市场广泛关注。此次股价暴跌主要受两大利空因素影响：公司宣布的可转债再融资计划以及美国银行的评级下调。
据悉，诺瓦瓦克斯医药计划发行2.25亿美元2031年到期的4.625%可转换债券。其中约1.753亿美元将用于换取1.487亿美元2027年到期的5.00%可转换债券，剩余部分约4970万美元将通过现金出售。新债券的转换价格定为每股11.14美元，较上一交易日收盘价溢价27.5%。这一举措虽然有助于公司优化债务结构，但也引发了市场对潜在股权稀释的担忧。
与此同时，美国银行对诺瓦瓦克斯医药的评级进行了下调，从"中性"调整为"跑输大市"，并将目标价从9美元下调至7美元。分析师的这一举动反映了对公司未来业务前景的担忧，尤其是在后疫情时代疫苗需求可能下降的背景下。这无疑给诺瓦瓦克斯医药的股价带来了进一步的下行压力。投资者将密切关注公司如何应对当前的市场挑战，以及其在疫苗领域的长期发展战略。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.